<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2018.810160</article-id><article-id pub-id-type="publisher-id">ACM-28128</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20181000000_24245570.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  原发性肝癌微小RNA的研究进展
  Advances in the Study of Micro-RNA inPrimary Liver Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>洪敬</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>冯</surname><given-names>将</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>建军</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>延安大学附属医院，陕西 延安</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>12</month><year>2018</year></pub-date><volume>08</volume><issue>10</issue><fpage>963</fpage><lpage>967</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    原发性肝癌是临床上常见的恶性肿瘤之一，由于其发生发展的隐匿性、快速性，多数患者确诊时已属中晚期，导致其病死率较高。因此，提高原发性肝癌的早期诊断率显得特别重要。目前，甲胎蛋白(AFP)已成为公认的肝癌筛查、诊断的血清标志物，但近年来发现，AFP阴性的原发性肝癌患者越来越多。并且在临床工作中发现单一检测AFP存在较高的漏诊率。因此，寻找特异度好、灵敏度高的肝癌特异性分子，是肝癌研究者一直努力的方向。目前，微小RNA (miRNA)在肿瘤发生和发展中的作用，已经成为生物医学领域的研究热点，miRNA的表达失衡与多种肿瘤的发生显著相关。其中，miR-122、miR-21是肝脏中高度特异性表达的miR。本文将对目前关于miR122、miR-21在原发性肝癌中特异性表现的相关研究进行综述。
    Primary hepatic carcinoma is one of the most common malignant tumors in clinical practice. Due to its insidious and rapid occurrence and development, most patients are in the middle and late stage at the time of diagnosis, resulting in high mortality. Therefore, it is very important to improve the early diagnosis rate of primary hepatic carcinoma. Currently, alphafetoprotein (AFP) has become a recognized serum marker for liver cancer screening and diagnosis, but in recent years, the number of primary hepatic carcinoma patients with AFP negative has been found to be increasing. In addition, a high rate of missed diagnosis of AFP was found in clinical work. Therefore, the search for specific molecules with good specificity and high sensitivity has been the direction of liver cancer researchers. At present, the role of microrna (miRNA) in tumorigenesis and development has become a research hotspot in the biomedical field, and the imbalance of miRNA expression is significantly correlated with the occurrence of multiple tumors. Among them, miR-122 and miR-21 are highly specifically expressed in liver. This paper reviews the current studies on the specific manifestations of miR122 and miR-21 in primary liver cancer. 
  
 
</p></abstract><kwd-group><kwd>原发性肝癌，微小RNA，miR-122，miR-21，早期诊断, Primary Hepatic Carcinoma</kwd><kwd> Microrna</kwd><kwd> MiR-122</kwd><kwd> MiR-21</kwd><kwd> Early Diagnosis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>原发性肝癌微小RNA的研究进展<sup> </sup></title><p>刘洪敬，冯将，杨建军</p><p>延安大学附属医院，陕西 延安</p><p><img src="//html.hanspub.org/file/15-1570729x1_hanspub.png" /></p><p>收稿日期：2018年11月30日；录用日期：2018年12月14日；发布日期：2018年12月21日</p><disp-formula id="hanspub.28128-formula10"><graphic xlink:href="//html.hanspub.org/file/15-1570729x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>原发性肝癌是临床上常见的恶性肿瘤之一，由于其发生发展的隐匿性、快速性，多数患者确诊时已属中晚期，导致其病死率较高。因此，提高原发性肝癌的早期诊断率显得特别重要。目前，甲胎蛋白(AFP)已成为公认的肝癌筛查、诊断的血清标志物，但近年来发现，AFP阴性的原发性肝癌患者越来越多。并且在临床工作中发现单一检测AFP存在较高的漏诊率。因此，寻找特异度好、灵敏度高的肝癌特异性分子，是肝癌研究者一直努力的方向。目前，微小RNA (miRNA)在肿瘤发生和发展中的作用，已经成为生物医学领域的研究热点，miRNA的表达失衡与多种肿瘤的发生显著相关 [<xref ref-type="bibr" rid="hanspub.28128-ref1">1</xref>] 。其中，miR-122、miR-21是肝脏中高度特异性表达的miR [<xref ref-type="bibr" rid="hanspub.28128-ref2">2</xref>] 。本文将对目前关于miR122、miR-21在原发性肝癌中特异性表现的相关研究进行综述。</p><p>关键词 :原发性肝癌，微小RNA，miR-122，miR-21，早期诊断</p><disp-formula id="hanspub.28128-formula11"><graphic xlink:href="//html.hanspub.org/file/15-1570729x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2018 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/15-1570729x7_hanspub.png" /> <img src="//html.hanspub.org/file/15-1570729x8_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>在全世界范围原发性肝癌每年新诊断病例超过80万，发病率居第六位，每年约有841,000例新发病例；死亡率居第四位，每年约有712,000死亡病例 [<xref ref-type="bibr" rid="hanspub.28128-ref3">3</xref>] 。原发性肝癌具有较高的发病率和死亡率，5年生存率不足10% [<xref ref-type="bibr" rid="hanspub.28128-ref4">4</xref>] 。原发性肝癌的病因是众多和复杂的，包括乙肝病毒感染、丙肝病毒感染、酗酒、黄曲霉毒素等，由于原发性肝癌发生发展的隐匿性、快速性，多数患者确诊时已属中晚期，错过了最佳治疗时机，导致其病死率较高 [<xref ref-type="bibr" rid="hanspub.28128-ref1">1</xref>] 。所以，原发性肝癌的早期诊断率得以提高显得特别重要。近年来，临床医生通过影像学检查(腹部B超、磁共振、增强CT等)和实验室指标(AFP、CA199等)诊断原发性肝癌。但是，对于早期肝癌诊断的精确度是不足的，尤其是直径小于3 cm的肝癌。目前，AFP已成为公认的肝癌筛查、诊断、治疗疗效、肿瘤复发等检测的主要手段，但近年来发现，AFP阴性的原发性肝癌患者越来越多。并且在临床工作中发现单一检测AFP存在较高的漏诊率。因此，寻找特异度好、灵敏度高的肝癌特异性分子，是肝癌研究者一直努力的方向，研究的热点。目前，微小RNA (miRNA)在肿瘤发生和发展中的作用，已经成为生物医学领域的研究热点，miRNA的表达失衡与多种肿瘤的发生显著相关 [<xref ref-type="bibr" rid="hanspub.28128-ref2">2</xref>] 。其中，miR-122、miR-21是肝脏中高度特异性表达的miR [<xref ref-type="bibr" rid="hanspub.28128-ref5">5</xref>] 。本文将对目前关于miR122、miR-21在原发性肝癌中特异性表现的相关研究进行综述。</p><p>miRNA是长度为21 nt~25 nt的单链非蛋白编码小RNA分子，它广泛存在于真核生物中。miRNA占生物体内总蛋白编码基因数量的1%~5%，能调控人类基因组10%~30%的基因在进化中具有高度的保守性。成熟的miRNA通过和其靶基因3’非翻译区(3’-UTR)作用，导致RNA诱导的沉默复合体降解其靶mRNA，或者阻碍其靶mRNA的翻译；miRNA可以作用于多个靶标调控基因表达，拥有多效性作用。在生物的整个发育过程中，miRNA可能会有调节细胞早期发育，参与固有免疫细胞生长分化和免疫应答，调节基因表达的生物学作用。miRNA广泛存在于正常和病理的细胞进程和组织中，发挥调控细胞周期、分化细胞等基本功能，可参与细胞增殖、生长、发育、分化、凋亡等过程的调控，且与肿瘤的发生、发展存在密切联系。研究发现，不同类型的肿瘤细胞或组织拥有其特殊的miRNA表达谱；miRNA在细胞周期进程中可以直接或间接地调控发挥作用的蛋白质分子，其表达水平的改变使得细胞周期进程失去控制，从而导致肿瘤的发生 [<xref ref-type="bibr" rid="hanspub.28128-ref5">5</xref>] - [<xref ref-type="bibr" rid="hanspub.28128-ref10">10</xref>] 。有研究表明，来源于肿瘤的miRNA避开了内源性核糖核酸酶的活性，在血液中能稳定存在，并且有一定的表达量，可以作为肿瘤标志物使用 [<xref ref-type="bibr" rid="hanspub.28128-ref11">11</xref>] 。</p></sec><sec id="s4"><title>2. miR122在原发性肝癌领域的研究进展</title><sec id="s4_1"><title>2.1. miR-122在肝癌细胞中的表达</title><p>在肝脏中，miR-122特异性高表达，其长度约为22个核苷酸，定位于18q21.31，而且miR-122是第一个被发现的肝脏特异性表达miRNA分子，该miRNA约占肝脏所表达miRNA分子总量的70% [<xref ref-type="bibr" rid="hanspub.28128-ref12">12</xref>] 。miR-122在肝细胞增殖、细胞生长、应激反应脂质代谢、基因表达以及肝细胞癌等多种生物学行为方面发挥着重要的调控作用，miR-122会在正常肝细胞中表达，但在肝癌细胞中表达水平则显著下调。miR-122表达水平的下调可以促进肿瘤的进展和转移，使肝癌的恶性特征明显提高 [<xref ref-type="bibr" rid="hanspub.28128-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.28128-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.28128-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.28128-ref16">16</xref>] 。恢复肝癌细胞或组织的miR-122表达水平可以逆转肝癌细胞的上皮样特征，明显降低其生长、侵袭、转移以及克隆形成能力，甚至可以降低其促血管生长的活性 [<xref ref-type="bibr" rid="hanspub.28128-ref17">17</xref>] 。</p></sec><sec id="s4_2"><title>2.2. miR-122在肝癌细胞增殖及凋亡的作用</title><p>Coulouarn等研究发现，肝癌细胞的miR-122表达下调会影响HNF1A、HNF3A和HNF3B的转录性调控导致肝癌的发生与发展 [<xref ref-type="bibr" rid="hanspub.28128-ref18">18</xref>] 。Fornari等研究发现，miR-122可以影响p53蛋白的转录活性和稳定性，从而进一步调节细胞周期蛋白CyclinG1的表达水平，最后降低癌细胞的侵袭能力。miR-122的靶点为去整合素—金属蛋白酶10 (ADAM10)、胰岛素样生长因子1受体(IGF1 R)和血清反应因子(SRF)，miR-122主要是通过阻止这些靶点来发挥作用，从而抑制肝细胞癌的发生。miR-122功能缺失导致癌症的发生。胰岛素样生长因子(IGF)的活性增加可以使肝癌的增殖能力提高 [<xref ref-type="bibr" rid="hanspub.28128-ref19">19</xref>] 。赵敏等通过选取26例原发性肝癌患者作为研究对象，采用原位杂交和流式细胞术检测方法，初步研究了miR-122的表达对肝癌细胞周期的影响，结果表明，miR-122表达阴性的肝癌组织中癌细胞S期的比例明显升高，G1-G0期比例降低，说明miR-122表达阴性的肝癌细胞拥有更加旺盛的增殖能力，表明miR-122在肝癌细胞中的表达下调可能通过一系列基因的表达变化，提高癌细胞的增值能力，使癌细胞的侵袭转移能力得以提高 [<xref ref-type="bibr" rid="hanspub.28128-ref16">16</xref>] 。</p></sec><sec id="s4_3"><title>2.3. 外周血miR-122 表达诊断原发性肝癌的展望</title><p>对肝癌高度特异性的miR-122的研究，使人们对细胞周期调控机制的认识更加丰富；同时对miR-122的进一步研究可能为原发性肝癌患者的诊断和治疗提供新思路、新方法。在肝癌细胞中miR-122表达缺失，可将其作为未来诊断和预测的指标之一。</p></sec></sec><sec id="s5"><title>3. miR-21在原发性肝癌领域的研究进展</title><sec id="s5_1"><title>3.1. miR-21 在肝癌细胞中的表达</title><p>miR-21是miRNAs家族中的重要成员，其定位于17q23.2染色体FRA17 B脆性区域上，是具有自主转录单位的一种microRNAs，它的成熟序列由长72 nt的茎环结构前体剪切加工而成。组织学的研究表明它参与了多种恶性肿瘤包括原发性肝癌的发生、发展，肿瘤组织中表达的miRNA水平与肿瘤生长、增值和远处转移有关 [<xref ref-type="bibr" rid="hanspub.28128-ref20">20</xref>] [<xref ref-type="bibr" rid="hanspub.28128-ref21">21</xref>] [<xref ref-type="bibr" rid="hanspub.28128-ref22">22</xref>] 。Meng等运用miRNA微阵列方法分析肝癌中miRNA，研究发现肝癌组织中miRNA-21的表达量高于正常肝组织5倍之多 [<xref ref-type="bibr" rid="hanspub.28128-ref21">21</xref>] 。原发性肝癌血清中miR-21的表达增高也已得到证实，王兴 [<xref ref-type="bibr" rid="hanspub.28128-ref23">23</xref>] 等研究显示：与正常及纤维化期大鼠相比较，miR-21在肝硬化期、肝癌早期、肝癌晚期的大鼠血清中都有不同程度的上调，而AFP只在肝癌早期、肝癌晚期的大鼠血清中出现了明显上调，这研究表明血清中miR-21的变化要早于AFP出现变化之前，而且miR-21的变化可能对肝癌发生发展过程中的各个阶段具有指示作用。</p></sec><sec id="s5_2"><title>3.2. miR-21在肝癌细胞增殖及凋亡中的作用</title><p>miRNA是一类内源性非编码小RNA，可以介导基因转录后沉默，从而调控基因表达。MiR-21在肝癌中高表达，其靶基因有抑癌基因PTEN、TPM1、PDCD4、和TIMP3等。张缨 [<xref ref-type="bibr" rid="hanspub.28128-ref10">10</xref>] 等研究表明：miR-21是PTEN的上游调控因子，PTEN是一种磷酸水解酶，其失活将会导致肿瘤发生。改变miR-21能引起PTEN的改变，从而发挥PTEN的抑癌功能，PTEN的抑癌作用主要是通过拮抗PI3 K/Akt信号系统发挥作用，诱导细胞周期阻滞。高表达的miR-21可以抑制PTEN的表达，继而激活PI3 K/Akt通路，导致肿瘤发生。在肝癌细胞及组织中miR-21过表达，而PTEN表达量下降，从而导致细胞增殖、转移、侵袭能力明显提高。因此认为，miR-21作为原癌基因，可以通过抑制抑癌基因PTEN，从而加速肝癌细胞的生长，增强侵袭和转移的能力。</p></sec><sec id="s5_3"><title>3.3. 外周血miR-21表达诊断原发性肝癌的研究</title><p>Xin Guo [<xref ref-type="bibr" rid="hanspub.28128-ref24">24</xref>] 等研究评估了miRNA-21作为一种新的血清标志物，对于原发性肝癌的诊断价值，描绘的ROC曲线证明miRNA-21曲线下面积为0.831，灵敏度82.1%，特异度83.9%，而且，在AFP阴性的肝癌患者群体中，miR-21仍然具有诊断价值(ROC曲线下的面积0.831，灵敏度81.2%，特异度83.2%)， miR-21能够鉴别原发性肝癌患者、慢性乙型肝炎、肝硬化，ROC曲线下的面积分别为0.789、0.814，灵敏度72.9%、80.8%，特异度85.7%、72.9%，另外，该研究表明血清学miR-21水平与肝癌的临床分期(P = 0.006)和远处转移(P = 0.000)有关。将血清中的miRNA作为今后肿瘤诊断和治疗靶点是一种精确和有前景的方法。有研究表明，miRNA能够稳定的在血浆中存在，并证实肿瘤衍生的miRNA存在血浆中并可以用来作为肿瘤诊断的生化指标。肝癌患者体内miR-21表达量上升提示预后不良，可作为诊断肝癌潜在的生物标志物。</p><p>目前在临床中，发挥辅助诊断肝癌作用的血清标志物较多，例如AFP、CA199、CEA等，但是它们对于早期肝癌的诊断存在着敏感度较低、特异性不足等缺点 [<xref ref-type="bibr" rid="hanspub.28128-ref25">25</xref>] [<xref ref-type="bibr" rid="hanspub.28128-ref26">26</xref>] 。AFP作为原发性肝癌特异性较高的血清标志物，在临床应用以来大大提高了肝癌的诊断准确率，研究结果显示AFP作为肝癌筛查工具的敏感性为39%~64%，特异性为76%~91%，对早期肝癌具有9%~32%阳性预测值，但仍有近1/3的原发性肝癌患者AFP为阴性，且区分肝癌与乙型肝炎或肝硬化的能力较差 [<xref ref-type="bibr" rid="hanspub.28128-ref25">25</xref>] [<xref ref-type="bibr" rid="hanspub.28128-ref26">26</xref>] 。因此，寻找一种新的敏感性及特异性更高的肝癌肿瘤标志物是迫切需要的，也是研究的热点。目前miRNA-122、miR-21在肝癌组织中的特异表达可以将其作为诊断原发性肝癌的一种血清标志物，将miRNA-122、miR-21与AFP等经典标志物进行联合检测，可以显著提高原发性肝癌诊断的敏感度和特异度，不过这一研究成果在临床上推广需要更多的循证证据来支持，相信将miRNA-122、miR-21与AFP进行联合检测诊断原发性肝癌会成为未来的研究趋势。</p></sec></sec><sec id="s6"><title>文章引用</title><p>刘洪敬,冯 将,杨建军. 原发性肝癌微小RNA的研究进展Advances in the Study of Micro-RNA inPrimary Liver Cancer[J]. 临床医学进展, 2018, 08(10): 963-967. https://doi.org/10.12677/ACM.2018.810160</p></sec><sec id="s7"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.28128-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Colagrande, S., Inghilesi, A.L., Aburas, S., et al. (2016) Challenges of Advanced Hepatocellular Carcinoma. World Journal of Gastroenterology, 22, 7645-7659. &lt;br&gt;https://doi.org/10.3748/wjg.v22.i34.7645</mixed-citation></ref><ref id="hanspub.28128-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Qi, J., Wang, J., Katayama, H., Sen, S. and Liu, S.M. (2013) Circulating MicroRNAs (cmiRNAs) as Novel Potential Biomarkers for Hepatocellular Carcinoma. Neoplasma, 60, 135-142. &lt;br&gt;https://doi.org/10.4149/neo_2013_018</mixed-citation></ref><ref id="hanspub.28128-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Bray, F., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 1-31. &lt;br&gt;https://doi.org/10.3322/caac.21492</mixed-citation></ref><ref id="hanspub.28128-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">EI-Serag, H.B. (2011) Hepatocellular Carcinoma. New England Journal of Medicine, 365, 1118-1127.  
&lt;br&gt;https://doi.org/10.1056/NEJMra1001683</mixed-citation></ref><ref id="hanspub.28128-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Huang, J.-T., et al. (2016) Systematic Review and Meta-Analysis: Circulating MiRNAs for Diagnosis of Hepatocellular Carcinoma. Journal of Cellular Physiology, 231, 328-335. &lt;br&gt;https://doi.org/10.1002/jcp.25135</mixed-citation></ref><ref id="hanspub.28128-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">常莹, 何星星, 黎培员, 等. Mi R-122调控肝癌遗传印迹基因PEGIO的实验研究[J]. 中华肝脏病杂志, 2010, 18(4): 288-291.</mixed-citation></ref><ref id="hanspub.28128-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">蒋永容, 陈川, 张志敏, 等. mi RNA.122a靶基因预测及生物信息学分析[J]. 中国肿瘤I临床, 2011, 38(16): 931-934.</mixed-citation></ref><ref id="hanspub.28128-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Xu, Y., Xia, F., Ma, L., et a1. (2011) Mi-croRNA-122 Sensitizes HCC Cancer Cells to Adriamycin and Vineristine through Modulating Expression of MDR and Inducing Cell Cycle Arrest. Cancer Letters, 310, 160-169.</mixed-citation></ref><ref id="hanspub.28128-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">张缨, 贾绍昌, 项方, 等. miR-122在肝癌细胞中的表达及其与细胞周期调控的关系[J]. 临床肿瘤学杂志, 2013, 18(8): 691-694.</mixed-citation></ref><ref id="hanspub.28128-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">张缨, 贾绍昌, 项方, 等. miR-21在肝癌细胞中的表达及其与抑癌基因PTEN的关系[J]. 临床肿瘤学杂志, 2014, 19(6): 490-493.</mixed-citation></ref><ref id="hanspub.28128-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Michell, P.S., Parkin, R.K., Kroh, E.N., et al. (2008) Circulating MicroRNAs as Stable Blood-Based Markers for Cancer Detection. Proceedings of the National Academy of Sciences of USA, 105, 10513-10518.  
&lt;br&gt;https://doi.org/10.1073/pnas.0804549105</mixed-citation></ref><ref id="hanspub.28128-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">马京香, 宫奇林, 林梅青, 等. 多项肿瘤标志物联合检测早期诊断原发性肝癌的研究[J]. 中华外科杂志, 2000, 38(1): 14-16.</mixed-citation></ref><ref id="hanspub.28128-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Bai, S., Nasser, M.W., Wang, B., et al. (2009) Micro RNA-122 Inhibits Tumorigenic Properties of Hepatocellular Carcinoma Cells and Sensitizes These Cells to So-rafenib. The Journal of Biological Chemistry, 284, 32015-32027.  
&lt;br&gt;https://doi.org/10.1074/jbc.M109.016774</mixed-citation></ref><ref id="hanspub.28128-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Ma, L., Liu, J., Shen, J., et al. (2010) Expression of mi R-122 Me-diated by Adenoviral Vector Induces Apoptosis and Cell Cycle Arrest of Cancer Cells. Cancer Biology &amp; Therapy, 9, 554-561. &lt;br&gt;https://doi.org/10.4161/cbt.9.7.11267</mixed-citation></ref><ref id="hanspub.28128-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, J., Yu, L., Gao, X., et al. (2011) Plasma Micro RNA Panel to Diagnose Hepatitis B Virus Related Hepatocellular Carcinoma. Journal of Clinical Oncology, 29, 478l-4788. &lt;br&gt;https://doi.org/10.1200/JCO.2011.38.2697</mixed-citation></ref><ref id="hanspub.28128-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">赵敏, 李贵柱, 邹强, 等. 肝癌组织miR-122的表达及其与细胞周期调控的关系[J]. 临床肿瘤学杂志, 2010, 15(5): 406-408.</mixed-citation></ref><ref id="hanspub.28128-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Wang, K.R., Yan, J.X., Zhang, B.Z., et al. (2009) Novel Mode of Action of Polybia MPI, a Novel Antimicrobial Peptide, in Multi-Drug Resist-Ant Leukenic Cells. Cancer Letters, 278, 65-72. &lt;br&gt;https://doi.org/10.1016/j.canlet.2008.12.027</mixed-citation></ref><ref id="hanspub.28128-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Coulouaru, C., Factor, V.M., Andersen, J.B., et al. (2009) Loss of miR-122 Expression in Liver Cancer Correlates with Suppression of the Hepat-ic-Phenotype and Gain of Metastatic Properties. Oncogene, 28, 3526-3536.</mixed-citation></ref><ref id="hanspub.28128-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Foruan, F., Gramantieri, L., Giovannini, C., et al. (2009) MiR122/cyclinG1 Interaction Modulates p53 Activity and Affects Doxorubicin Sensitivity of Human Hepatocarcinoma Cells. Cancer Research, 69, 5761-5767.  
&lt;br&gt;https://doi.org/10.1158/0008-5472.CAN-08-4797</mixed-citation></ref><ref id="hanspub.28128-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Krichevsky, A.M. and Gabriely, G. (2009) MiR-21: A Small Multi-Faceted RNA. Journal of Cellular and Molecular Medicine, 13, 39-53. &lt;br&gt;https://doi.org/10.1111/j.1582-4934.2008.00556.x</mixed-citation></ref><ref id="hanspub.28128-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Meng, F., Henson, R., Wehbe-Janek, H., et al. (2007) Micro RNA-21 Regulates Expression of the PTEN Tumor Suppressor Gene in Human Hepatocellular Cancer. Gastroenterology, 133, 647-658.  
&lt;br&gt;https://doi.org/10.1053/j.gastro.2007.05.022</mixed-citation></ref><ref id="hanspub.28128-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Connolly, E., Melegari, M., Landgraf, P., et al. (2008) Elevated Expression of the miR-17-92 Polycistron and miR-21 in Hepadnavirus-Associated Hepato-Cellular Carcinoma Contributes to the Malignant Phenotype. The American Journal of Pathology, 173, 856-864. &lt;br&gt;https://doi.org/10.2353/ajpath.2008.080096</mixed-citation></ref><ref id="hanspub.28128-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">王兴, 张娟, 夏宁, 等. 血清miR-21及AFP在大鼠肝癌发生过程中的动态表达比较分析[J]. 现代生物医学进展, 2012, 12(12): 2282-2297.</mixed-citation></ref><ref id="hanspub.28128-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Guo, X., Lv, X., Lv, X., et al. (2017) Circulating miR-21 Serves as a Serum Biomarker for Hepatocellular Carcinoma and Correlated with Distant Metastasis. Oncotarget, 8, 44050-44058.</mixed-citation></ref><ref id="hanspub.28128-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">姜英丽, 陈虹. 肝癌早期诊断标志物的研究进展[J]. 中国医学工程, 2011(4): 169-170.</mixed-citation></ref><ref id="hanspub.28128-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Song, K., Hyunjoo, K., Han, C., et al. (2015) Active Glycolytic Metabolism in CD133+ Hepatocellular Cancer Stem Cells: Regulation by miR-122. Oncotarget, 6, 40822-40835.</mixed-citation></ref></ref-list></back></article>